CPA
YMAB

Capital Performance Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

Capital Performance Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3
Closed -$39 – 2753
2024
Q3 		$39 Buy
+3
New +$38 ﹤0.01% 2814

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Performance Advisors's YMAB Position: Q4 2024 in Review

Capital Performance Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q4 2024, closing a stake of 3 shares — an estimated $39 sold.

Capital Performance Advisors first reported a position in YMAB in Q3 2024 and held it in 1 quarter. The position peaked at $39 in Q3 2024. 112 funds tracked by Wall St. Rank hold YMAB as of Q4 2024.

  • Capital Performance Advisors reported no remaining Y-mAbs Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 3 Y-mAbs Therapeutics shares in Q4 2024, an estimated $39.
  • Capital Performance Advisors first reported a position in Y-mAbs Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Y-mAbs Therapeutics position peaked at $39 in Q3 2024.
  • 112 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.